Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
Status:
Not yet recruiting
Trial end date:
2026-12-23
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the effect of treatment with olpasiran, to
placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or
urgent coronary revascularization in participants with atherosclerotic cardiovascular disease
(ASCVD) and elevated Lipoprotein(a).